Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells

Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells

In this study, we investigated the efficacy of methyl-cantharidimide (MCA), a cantharidin (CTD) analog, as an anticancer drug, in cancer cells overexpressing either ABCB1 or ABCG2 transporters and in cisplatin-resistant cancer cells. The results indicated that: (i) MCA was efficacious in the ABCB1-o...

Full description

Bibliographic Details
Main Authors: Yi-Dong Li, Yong Mao, Xing-Duo Dong, Zi-Ning Lei, Yuqi Yang, Lizhu Lin, Charles R. Ashby, Dong-Hua Yang, Ying-Fang Fan, Zhe-Sheng Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Oncology
Subjects:
methyl-cantharidimide (MCA)
multidrug resistance (MDR)
ABCB1
ABCG2
cisplatin resistance
cell apoptosis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00932/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00932/full

Similar Items